Fenwick represented Merck Global Health Innovation Fund (Merck GHI) in the sale of Preventice Solutions, a privately held company which offers a full portfolio of mobile cardiac health solutions and services, to Boston Scientific. Preventice’s primary investors included Merck GHI, Boston Scientific, Vivo Capital and Novo Holdings A/S.
The transaction consisted of an upfront cash payment by Boston Scientific (who held a ~22% stake in Preventice) to the other shareholders of Preventice of ~$720 million, with up to an additional ~$230 million in a potential commercial milestone payment. More information can be obtained from Boston Scientific’s announcement.
The Fenwick transaction team included corporate partners Ian Goldstein and Ethan Skerry and associate Victoria Lupu.
Fenwick has served as outside counsel to Merck GHI since 2016, representing the corporate venture arm in dozens of healthcare investments, including its participation in Preventice’s $137 million Series B financing.